Business
Allogene Therapeutics Reports First Quarter 2025 Financial Results and Business Update
Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL) Nearly 50 Sites Activated Across U.S. with Strong Enthusiasm from InvestigatorsLymphodepletion Selection and Futility Analysis Shifted to 1H 2026 in Part Due to Site-Related Factors that Impacted Expected Pace of Screening Immediately Following Site ActivationOver 250 Patients Consented for MRD Screening to Date, with Nearly Half in the Last Three Months and A
About this update from Allogene Therapeutics, Inc.
[{"type":"image","alt":"Allogene Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Allogene Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":126,"url":"https://media.zenfs.com/en/globenewswire.com/e1380caace874bf039771959c9835030"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QCsYA1reL6jmKogB1ZpqzA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE3NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e1380caace874bf039771959c9835030","width":300,"height":126}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Pivotal Phase 2 ALPHA3 Trial with Cemacabtagene Ansegedleucel (Cema-Cel) in First Line (1L) Consolidation in Large B-Cell Lymphoma (LBCL)","length":137,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Nearly 50 Sites Activated Across U.S. with Strong Enthusiasm from Investigators","length":79,"tagName":"p"}]},{"val":[{"type":"text","content":"Lymphodepletion Selection and Futility Analysis Shifted to 1H 2026 in Part Due to Site-Related Factors that Impacted Expected Pace of Screening Immediately Following Site Activation","length":181,"tagName":"p"}]},{"val":[{"type":"text","content":"Over 250 Patients Consented for MRD Screening to Date, with Nearly Half in the Last Three Months and Awaiting Completion of 1L Treatment as Earliest Activated Sites Build Momentum","length":179,"tagName":"p"}]},{"val":[{"type":"text","content":"International Expansion of ALPHA3 Trial to Begin with Site Activations in Canada in Q2 2025","length":91,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":530,"olType":false}]},{"val":[{"type":"text","content":"Phase 1 RESOLUTION Trial with ALLO-329 in Autoimmune Disease (AID)","length":66,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"RESOLUTION Basket Trial in Rheumatology on Track for Mid-2025 Start","length":67,"tagName":"p"}]},{"val":[{"type":"text","content":"Proof-of-Concept Data Moved to 1H 2026 to Enable Inclusion of Both Biomarker and Clinical Data","length":99,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":166,"olType":false}]},{"val":[{"type":"text","content":"Phase 1 TRAVERSE Trial with ALLO-316 in Renal Cell Carcinoma (RCC)","length":66,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Updated Phase 1 Trial Results Will be F...